Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.

• Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies · 2022

• Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation · 2022

  Not checked

• Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission · 2022

• COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron) · 2022

  Not checked

• Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core · 2022

  Not checked

• SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History · 2022

  Not checked

• Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational Study · 2022

  Not checked

• Psychological research of the children with chronic kidney disease and their guardians during the COVID-19 pandemic · 2022

  Not checked

• SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort · 2022

  Not checked

• Association of Online Search Trends With Vaccination in the United States: June 2020 Through May 2021 · 2022

  Not checked

• Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa · 2022

• Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS‐CoV‐2 vaccine · 2022

  Not checked

• The emergence, dynamics and significance of SARS-CoV-2 variants · 2022

  Not checked

• Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection · 2022

• SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022

• Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies · 2022

• The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans · 2022

• SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022

• Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination · 2022

• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022

and 13 more

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.